Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | PRCP | P42785 | 1/20 | 0.40 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.40 |
| ▸ | OPRM1 | P35372 | 4/20 | 0.38 |
| ▸ | OPRL1 | P41146 | 4/20 | 0.38 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.38 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.38 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.37 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.37 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.37 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.37 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.37 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.36 |
| ▸ | CCR1 | P32246 | 1/20 | 0.34 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.34 |
| ▸ | APBA1 | Q02410 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11066529 | 0.75 | CYP1A2 (0.33) | SLC6A3SLC6A2SLC6A4 | |
| SCHEMBL1152677 | 0.73 | OPRM1 (0.49) | KMT2ASIGMAR1OPRM1OPRD1OPRK1 | |
| SCHEMBL5754493 | 0.72 | CHRM1 (0.37) | OPRM1OPRD1CHRM1 | |
| SCHEMBL13229259 | 0.71 | OPRM1 (0.51) | KMT2AMEN1PRCPSIGMAR1OPRM1 | |
| SCHEMBL11072043 | 0.70 | CYP1A2 (0.40) | SIGMAR1OPRM1OPRL1OPRD1OPRK1 | |
| SCHEMBL10637823 | 0.70 | CYP3A4 (0.35) | OPRM1OPRD1OPRK1ALDH1A1MAPT | |
| SCHEMBL10640876 | 0.69 | OPRM1 (0.49) | KMT2AMEN1OPRM1OPRL1OPRD1 | |
| SCHEMBL10641018 | 0.69 | POLB (0.42) | OPRM1MAPTNPC1RAB9ATSHR | |
| SCHEMBL10637222 | 0.68 | OPRM1 (0.50) | KMT2AMEN1OPRM1SLC6A3SLC6A2 | |
| SCHEMBL10637592 | 0.68 | OPRM1 (0.46) | KMT2ASIGMAR1OPRM1SLC6A3SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1441718-B1 | USE OF CARBINOLS FOR THE TREATMENT OF NEUROPATHIC DYSFUNCTION | ENDO PHARMACEUTICALS INC (US) | 2006-07-12 | — | — | EP | claimed |
| EP-1441718-A4 | CARBINOLS FOR THE TREATMENT OF NEUROPATHIC DYSFUNCTION | ENDO PHARMACEUTICALS INC (US) | 2005-08-17 | — | — | EP | claimed |
| US-6825217-B2 | HETEROCYCLIC AMINES SUCH AS 4-(3'-THIENYL)-ALPHA, ALPHA, 1-TRIMETHYL-4-PIPERIDINEMETHANOL AND/OR PRODRUGS, USED AS ANALGESICS FOR PROPHYLAXIS OF NEUROPATHIC PAIN | ENDO PHARMACEUTICALS, INC. | 2004-11-30 | — | — | US | claimed |
| EP-1441718-A2 | CARBINOLS FOR THE TREATMENT OF NEUROPATHIC DYSFUNCTION | Endo Pharmaceuticals Inc. (US) | 2004-08-04 | — | — | EP | claimed |
| US-20030162811-A1 | Carbinols for the treatment of neuropathic dysfunction | ENDO PHARMACEUTICALS INC. | 2003-08-28 | — | — | US | claimed |
| WO-2003032910-A2 | CARBINOLS FOR THE TREATMENT OF NEUROPATHIC DYSFUNCTION | ENDO PHARMACEUTICALS INC. (US) | 2003-04-24 | — | — | WO | claimed |
| EP-1441718-B1 | USE OF CARBINOLS FOR THE TREATMENT OF NEUROPATHIC DYSFUNCTION | ENDO PHARMACEUTICALS INC (US) | 2006-07-12 | — | — | EP | disclosed |
| EP-1441718-A4 | CARBINOLS FOR THE TREATMENT OF NEUROPATHIC DYSFUNCTION | ENDO PHARMACEUTICALS INC (US) | 2005-08-17 | — | — | EP | disclosed |
| US-20050026956-A1 | 3-Aryl-3-pyrrolidinemethanol, 4-aryl-4-piperidinemethanol, or 4-aryl-4-azepinemethanol derivatives; 4-(3-thienyl)- alpha , alpha ,1,1-trimethyl-4-piperidinemethanol; tumors, diabetes, arthritis; autoimmune, genetic, demyelination, and rheumatic disorders; antiinflammatory agents | ENDO PHARMACEUTICALS, INC., A DELAWARE CORPORATION (US) | 2005-02-03 | — | — | US | disclosed |
| US-6825217-B2 | HETEROCYCLIC AMINES SUCH AS 4-(3'-THIENYL)-ALPHA, ALPHA, 1-TRIMETHYL-4-PIPERIDINEMETHANOL AND/OR PRODRUGS, USED AS ANALGESICS FOR PROPHYLAXIS OF NEUROPATHIC PAIN | ENDO PHARMACEUTICALS, INC. | 2004-11-30 | — | — | US | disclosed |
| EP-1441718-A2 | CARBINOLS FOR THE TREATMENT OF NEUROPATHIC DYSFUNCTION | Endo Pharmaceuticals Inc. (US) | 2004-08-04 | — | — | EP | disclosed |
| WO-2003032910-A2 | CARBINOLS FOR THE TREATMENT OF NEUROPATHIC DYSFUNCTION | ENDO PHARMACEUTICALS INC. (US) | 2003-04-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030162811-A1 | Carbinols for the treatment of neuropathic dysfunction | CNR2, CNR1, OPRL1 | KMT2A 3676/4885MEN1 4044/4885PRCP 2156/4885 |
| US-20050026956-A1 | 3-Aryl-3-pyrrolidinemethanol, 4-aryl-4-piperidinemethanol, or 4-aryl-4-azepinemethanol derivatives; 4-(3-thienyl)- alpha , alpha ,1,1-trimethyl-4-piperidinemethanol; tumors, diabetes, arthritis; autoimmune, genetic, demyelination, and rheumatic disorders; antiinflammatory agents | PMP22, NAT1, MAG | KMT2A 844/4885MEN1 1395/4885PRCP 3121/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.